PURPOSE: As a progressive condition, glaucoma may impair health-related quality of life (HRQoL), due to vision loss and other factors. This study evaluated HRQoL in a cohort of patients treated for primary open-angle glaucoma (POAG) and assessed its association with clinical features. METHODS: This was an Italian, multicentre, cross-sectional, observational study with the subgroup of newly diagnosed patients with POAG prospectively followed up for one year. Patients with previous or new diagnosis (or strong clinical suspicion) of POAG aged >18 years were considered eligible. Information was collected on demographic characteristics, medical history, clinical presentation and POAG treatments. HRQoL was measured using the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and Glaucoma Symptom Scale (GSS). Subscale and total scores were obtained and a Pearson correlation coefficient between instruments' scores calculated. RESULTS: A total of 3227 patients were enrolled from 2012 to 2013 and 3169 were analysed. Mean age was 66.9 years. A total of 93.8% had a previous diagnosis (median duration: 8.0 years). Median values for mean deviation and pattern standard deviation were 3.9 and 3.6 dB, respectively. Mean scores on most subscales of the NEI-VFQ-25 exceeded 75.0 and mean GSS subscale scores ranged between 70.8 and 79.7 (with a total mean score of 74.8). HRQoL scores on both scales were significantly inversely associated with POAG severity. CONCLUSION: In this large sample of Italians treated for POAG, disease severity was limited and HRQoL scores were high. QoL decreased with advancing disease severity. These findings confirm the role of vision loss in impairing QoL in POAG, underlying the importance of timely detection and appropriate treatment.
PURPOSE: As a progressive condition, glaucoma may impair health-related quality of life (HRQoL), due to vision loss and other factors. This study evaluated HRQoL in a cohort of patients treated for primary open-angle glaucoma (POAG) and assessed its association with clinical features. METHODS: This was an Italian, multicentre, cross-sectional, observational study with the subgroup of newly diagnosed patients with POAG prospectively followed up for one year. Patients with previous or new diagnosis (or strong clinical suspicion) of POAG aged >18 years were considered eligible. Information was collected on demographic characteristics, medical history, clinical presentation and POAG treatments. HRQoL was measured using the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and Glaucoma Symptom Scale (GSS). Subscale and total scores were obtained and a Pearson correlation coefficient between instruments' scores calculated. RESULTS: A total of 3227 patients were enrolled from 2012 to 2013 and 3169 were analysed. Mean age was 66.9 years. A total of 93.8% had a previous diagnosis (median duration: 8.0 years). Median values for mean deviation and pattern standard deviation were 3.9 and 3.6 dB, respectively. Mean scores on most subscales of the NEI-VFQ-25 exceeded 75.0 and mean GSS subscale scores ranged between 70.8 and 79.7 (with a total mean score of 74.8). HRQoL scores on both scales were significantly inversely associated with POAG severity. CONCLUSION: In this large sample of Italians treated for POAG, disease severity was limited and HRQoL scores were high. QoL decreased with advancing disease severity. These findings confirm the role of vision loss in impairing QoL in POAG, underlying the importance of timely detection and appropriate treatment.
Authors: Naira Khachatryan; Maxwell Pistilli; Maureen G Maguire; Angela Y Chang; Marissa R Samuels; Kristen Mulvihill; Rebecca J Salowe; Joan M O'Brien Journal: Ophthalmic Epidemiol Date: 2021-02-03
Authors: Gabriel Lazcano-Gomez; María de Los Angeles Ramos-Cadena; Margarita Torres-Tamayo; Alejandra Hernandez de Oteyza; Mauricio Turati-Acosta; Jesús Jimenez-Román Journal: Medicine (Baltimore) Date: 2016-11 Impact factor: 1.889
Authors: Ivano Riva; Lorenzo Legramandi; Eliana Rulli; Anastasios G Konstas; Andreas Katsanos; Francesco Oddone; Robert N Weinreb; Luciano Quaranta Journal: Sci Rep Date: 2019-05-01 Impact factor: 4.379
Authors: Ľudmila Majerníková; Anna Hudáková; Andrea Obročníková; Beáta Grešš Halász; Mária Kaščáková Journal: Int J Environ Res Public Health Date: 2021-01-09 Impact factor: 3.390
Authors: Giuseppe Giannaccare; Marco Pellegrini; Carlotta Senni; Federico Bernabei; Vincenzo Scorcia; Arrigo Francesco Giuseppe Cicero Journal: Mar Drugs Date: 2020-05-01 Impact factor: 5.118